Bristol Myers Squibb (BMY) Inventory (2009 - 2026)
Bristol Myers Squibb (BMY) reported Inventory of $2.8 billion for Q1 2026, up 3.38% year-over-year from $2.7 billion in Q1 2025, and up 2.45% quarter-over-quarter from $2.7 billion in Q4 2025.
Bristol Myers Squibb (BMY) Inventory (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (BMY) has 18 years of Inventory data on file, last reported at $2.8 billion in Q1 2026.
- Inventory for Q1 2026 came in at $2.8 billion, up 3.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.8 billion (up 3.38% YoY), and the FY2025 annual result was $2.7 billion, up 5.2% from the prior year.
- Inventory grew to $2.8 billion in Q1 2026 per BMY's latest filing, from $2.7 billion in the prior quarter.
- Over five years, Inventory peaked at $3.3 billion in Q3 2024 and troughed at $2.1 billion in Q3 2022.
- A 5-year average of $2.6 billion and a median of $2.7 billion in 2023 frame the typical range for Inventory.
- The sharpest annual moves came in 2024 and 2025: Inventory soared 36.78% in 2024, then dropped 17.23% in 2025.
- A 5-year view of Inventory shows it stood at $2.3 billion in 2022, then rose by 13.81% to $2.7 billion in 2023, then decreased by 3.94% to $2.6 billion in 2024, then increased by 5.2% to $2.7 billion in 2025, then gained by 2.45% to $2.8 billion in 2026.
- Business Quant data shows BMY's Inventory at $2.8 billion in Q1 2026, $2.7 billion in Q4 2025, and $2.8 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 8.30 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 14.53 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 14.58 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 5.05 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 6.48 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 6.19 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.91 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 10.67 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.76 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.76 Bn |
| Dec 31, 2025 | 2.69 Bn |
| Sep 30, 2025 | 2.76 Bn |
| Jun 30, 2025 | 2.74 Bn |
| Mar 31, 2025 | 2.67 Bn |
| Dec 31, 2024 | 2.56 Bn |
| Sep 30, 2024 | 3.33 Bn |
| Jun 30, 2024 | 3.08 Bn |
| Mar 31, 2024 | 2.99 Bn |
| Dec 31, 2023 | 2.66 Bn |
| Sep 30, 2023 | 2.44 Bn |
| Jun 30, 2023 | 2.36 Bn |
| Mar 31, 2023 | 2.61 Bn |
| Dec 31, 2022 | 2.34 Bn |
| Sep 30, 2022 | 2.07 Bn |
| Jun 30, 2022 | 2.14 Bn |
| Mar 31, 2022 | 2.10 Bn |
| Dec 31, 2021 | 2.10 Bn |
| Sep 30, 2021 | 2.16 Bn |
| Jun 30, 2021 | 2.14 Bn |